Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer... see more

Recent & Breaking News (NDAQ:BYSI)

BeyondSpring Announces $20 Million Registered Direct Offering

GlobeNewswire May 30, 2018

BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting

GlobeNewswire May 17, 2018

BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference

GlobeNewswire May 7, 2018

BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia

GlobeNewswire April 17, 2018

BeyondSpring Files Its 2017 Annual Report on Form 20-F

GlobeNewswire April 3, 2018

BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results

GlobeNewswire April 3, 2018

Earnings Scheduled For April 3, 2018

Benzinga.com  April 3, 2018

BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018

GlobeNewswire March 27, 2018

BeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer

GlobeNewswire March 27, 2018

BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

GlobeNewswire March 19, 2018

BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018

GlobeNewswire March 15, 2018

BeyondSpring to Present at Upcoming Investor Conferences

GlobeNewswire February 7, 2018

BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

GlobeNewswire February 5, 2018

BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

GlobeNewswire January 26, 2018

BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

GlobeNewswire January 17, 2018

BeyondSpring to Present at the 10th Annual Biotech Showcase

GlobeNewswire January 5, 2018

BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member

GlobeNewswire January 3, 2018

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)

GlobeNewswire December 14, 2017

BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017

GlobeNewswire December 7, 2017

BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

GlobeNewswire December 4, 2017